Emcure Pharmaceuticals IPO Sees 1.32x Subscription on Day 1

On the first day of the bidding process, Emcure Pharmaceuticals Limited IPO was subscribed 1.32 times. The retail portion was subscribed to 1.41x, 0.07x in Qualified Institutional Buyers (QIB), 2.76x in Non-Institutional Investors (NII), and 2.25x in the employees category.

The IPO opened today, July 3, 2024, and will close on July 5, 2024. The allotment for the Emcure Pharma IPO is scheduled to be finalised on Monday, July 8, 2024. The IPO is set to list on both the BSE and NSE, with a tentative listing date of Wednesday, July 10, 2024.

On July 3, 2024, unlisted shares of Emcure Pharmaceuticals Ltd were trading at ₹310 in the grey market.

Emcure Pharmaceuticals Ltd’s IPO price range has been set at ₹960 to ₹1,008 per share. The minimum lot size is 14 shares, and the minimum investment required by retail investors is ₹14,112. The IPO comprises both a fresh issue and an Offer For Sale (OFS), with a total issue size of 19,365,346 shares aggregating up to ₹1,952.03 crore.

The object of the Emcure Pharmaceuticals Limited IPO is to repay and/or prepay all or a portion of certain outstanding borrowings availed by the company and general corporate purposes.

On July 2, 2024, the company’s IPO committee along with the book-running lead managers, finalised the allocation of 57,79,850 equity shares to Anchor Investors at an Anchor Investor allocation price of ₹1,008 per equity share.

About Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Ltd is an Indian pharmaceutical firm that focuses on research, development, manufacturing, and global marketing of a diverse range of pharmaceutical products. Their portfolio spans orals, injectables, and biotherapeutics, catering to markets in more than 70 countries, with significant operations in India, Europe, and Canada.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.